The Lynx Group
Cholangiocarcinoma News

Biomarker Testing and Imaging in Cholangiocarcinoma

December 2021, Vol 2, No 4

New biomarker technologies may be combined with cholangiocarcinoma (CCA) characteristics to predict patient response to treatment, according to presenters at Session V, “Biomarker Testing in CCA: New Technologies/Imaging as a Biomarker,” during the 3rd Annual CCA Summit.

James Costello, MD, PhD, Moffitt Cancer Center, Tampa, FL, discussed enhancement patterns of computed tomography (CT) and magnetic resonance imaging (MRI). Intrahepatic CCA with a hypovascular enhancement pattern shows worse disease-free survival than hypervascular or rim-enhancing intrahepatic CCA.

Patients with scirrhous-type intrahepatic CCA also have lower overall survival. In contrast, patients with hypervascular patterns of intrahepatic CCA have prolonged overall survival.

“With MRI, we have the ability to administer extracellular contrast agents and also hepatocyte-specific contrast agents, which are excreted into the biliary system,” said Dr Costello. “These hepatocyte-specific contrast agents allow us to generate 20-minute delayed hepatobiliary phase images, where we can assess the tumors for how they enhance at that 20-minute delayed time point.”

Dual-energy CT uses dual acquisition at different kilovoltage levels, providing image reconstruction techniques. Dual-energy CT may also be useful for assessing response to treatment, because it demonstrates intratumor heterogeneity. Positron-emission tomography and CT scans have been used for detection of distant metastases, lymph node staging, and to investigate the genetic makeup of tumors noninvasively.

Diffusion-weighted imaging evaluates random Brownian motion of water molecules between intracellular and extracellular compartments. The apparent diffusion coefficient (ADC) map can provide insight into a tumor viability and structure: viable tumors have low ADC values and cellular necrosis results in higher ADC values, according to Dr Costello. Diffusion-weighted imaging can also be used for diagnosis and tumor grade: lower ADC values are associated with a diagnosis of a higher tumor grade. Response to treatment can also be reflected by a continuous increase in ADC values.

Magnetic resonance relaxometry can be used to quantify imaging biomarkers that reflect tissue biophysical properties. T1 mapping characterizes longitudinal relaxation and can be used to evaluate response to therapy and tissue fibrosis or extracellular changes. T2 mapping reflects the rate that the transverse magnetization decays to zero. Malignant masses have lower T2 values than benign masses.

“What becomes incumbent upon us is trying to figure out a pattern among all of the data,” said Dr Costello.

Laurent Dercle, MD, PhD, Columbia University Irving Medical Center, New York City, discussed how new imaging technologies, such as AI and radiomics, offer an objective approach that may guide clinical decision-making and the potential role of imaging as a biomarker.

Elevated tumor burden shortens overall survival. The location of metastatic involvement has been linked to survival and to response to treatment. Patient anthropomorphic characteristics, including skeletal muscle index, are associated with patient survival. AI has been used to develop a radiomics signature that is associated with patient survival. Bone marrow metabolism can also be used to predict bone marrow and spleen metabolism, overall survival, and transcriptomics.

“We are demonstrating that [imaging biomarkers] can also be combined with clinical and biological characteristics,” said Dr Dercle.

“From a broader perspective, we think that there is a need to develop advanced imaging technology, and there is a need to develop comprehensive programs of radiomics, to develop probabilistic and predictive tools that could improve the diagnosis and assessment of response in cancer patients,” he concluded.

Related Items

New Frontiers in Surgery for CCA
By Skye Mayo, MD, MPH, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Videos
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Transplantation in iCCA
By Keri Lunsford, MD, PhD, FACS; Maria B. Majella Doyle, MD, MBA, FRCSI, FACS
Videos
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
New Pathways and Molecular Targets in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Potential therapeutic targets for cholangiocarcinoma (CCA) include oncogenic pathways and other options, such as epigenetics, posttranslational modifications, and metabolism, according to presentations delivered during Session I, “Advances in Translational/Molecular Targets in CCA: New Molecular Targets/Pathways in CCA,” at the 3rd Annual CCA Summit.
Molecular Epidemiology of Cholangiocarcinoma: Identifying New Inherited Variants
By Erin Burns, PhD
December 2021, Vol 2, No 4
Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.”
The Future of Chemotherapy in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Personalization of therapy and novel regimens are needed to improve options for patients with cholangiocarcinoma (CCA).
Understanding Predictive Biomarkers and Resistance to Immunotherapy in Biliary Tract Cancers
By Erin Burns, PhD
December 2021, Vol 2, No 4
Improved understanding of predictive biomarkers is needed in immuno-oncology, and various immunotherapy combinations using different mechanisms of action are being investigated in cholangiocarcinoma (CCA) and other biliary tract cancers, according to presentations delivered at Session IV, “What’s New in Immuno-­oncology in BTC? Monotherapy and Combo Therapies,” at the 3rd Annual CCA Summit.
Resistance Mechanisms and Adverse Events Associated with Targeted Therapy in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit.
Expert Perspective on the Evolving Standard of Care in Biliary Tract Cancers
By Erin Burns, PhD
December 2021, Vol 2, No 4
Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert Keynote Perspective at the 3rd Annual Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangio­carci­noma (CCA), with liquid biopsy becoming the tool of choice for geno­mic profiling in biliary tract cancers.
Hot Topics in Cholangiocarcinoma and Biliary Tract Cancer Discussed at Recent 2021 Meetings
By Erin Burns, PhD
December 2021, Vol 2, No 4
Rachna T. Shroff, MD, MS, University of Arizona Cancer Center, Tucson, delivered a Keynote Review at the 3rd Annual Summit of studies presented in several 2021 national and international meetings, highlighting advances in treatments targeting FGFR2, IDH1, and HER2 mutations and other alterations that led to recently approved new therapies. She reminded attendees that in 2021, 2 new targeted therapies have been approved by the FDA for patients with cholangiocarcinoma (CCA).
Next-Generation Sequencing and Interventional Oncology in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
The benefits of next-generation sequencing, liquid biopsy, the need for integration of local and systemic therapies, advanced intraductal interventions, and advanced radiotherapy technologies in biliary tract cancers were addressed in Session VII, “Interventional Oncology and Locoregional Therapy,” at the 3rd Annual CCA Summit.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: